mTOR in health and in sickness
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605543542 | ||
| 003 | CHVBK | ||
| 005 | 20210128100927.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00109-015-1326-7 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00109-015-1326-7 | ||
| 245 | 0 | 0 | |a mTOR in health and in sickness |h [Elektronische Daten] |c [Dritan Liko, Michael Hall] |
| 520 | 3 | |a Target of rapamycin (TOR) is a highly conserved protein kinase that plays a key role in mediating cell growth and homeostasis. It is activated by nutrients, growth factors, and cellular energy levels to control a number of anabolic and catabolic processes. It is a validated drug target implicated in a variety of diseases. In this review, we describe the molecular mode of action of TOR in the context of cellular and organismal physiology. We focus on mammalian TOR (mTOR) signaling in cancer and neurological disease and discuss usage of TOR inhibitors in the clinic. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2015 | ||
| 690 | 7 | |a mTOR |2 nationallicence | |
| 690 | 7 | |a Health |2 nationallicence | |
| 690 | 7 | |a TOR |2 nationallicence | |
| 690 | 7 | |a mTORC1 |2 nationallicence | |
| 690 | 7 | |a mTORC2 |2 nationallicence | |
| 690 | 7 | |a mTOR inhibitors |2 nationallicence | |
| 690 | 7 | |a Rapamycin |2 nationallicence | |
| 690 | 7 | |a Rapalogs |2 nationallicence | |
| 690 | 7 | |a Disease |2 nationallicence | |
| 700 | 1 | |a Liko |D Dritan |u Biozentrum, University of Basel, 4056, Basel, Switzerland |4 aut | |
| 700 | 1 | |a Hall |D Michael |u Biozentrum, University of Basel, 4056, Basel, Switzerland |4 aut | |
| 773 | 0 | |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/10(2015-10-01), 1061-1073 |x 0946-2716 |q 93:10<1061 |1 2015 |2 93 |o 109 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00109-015-1326-7 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00109-015-1326-7 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Liko |D Dritan |u Biozentrum, University of Basel, 4056, Basel, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hall |D Michael |u Biozentrum, University of Basel, 4056, Basel, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Molecular Medicine |d Springer Berlin Heidelberg |g 93/10(2015-10-01), 1061-1073 |x 0946-2716 |q 93:10<1061 |1 2015 |2 93 |o 109 | ||